DECN to Discuss Three Major Events After Memorial Day Holiday Company Plans to Communicate 3rd Offer for the Monitizing Its New "TBG" Products, Developments in Big Box Efforts And the J&J Litigation
LOS ANGELES, CA - May 23, 2019 - Decision Diagnostics Corp. (OTC: DECN) – Keith Berman CEO of the FDA registered 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, etc is announcing that beginning next week we will discuss the following issues in detail, Read More. See Complete Information: http://www.thestreetnow.com/spotlight/dailynews/